SelinaLugerMD

Hematology • Philadelphia, PA

Professor of Medicine, University of Pennsylvania

Join to view full profile

Dr. Luger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Luger's full profile

Already have an account?

Office
3400 Civic Center Blvd,
Perelman Center for Advanced Medicine 2 West
Philadelphia, PA 19104
Phone+1 215-662-6348

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1990 - 1993
UPMC Medical EducationResidency, Internal Medicine, 1987 - 1990
McGill University Faculty of MedicineClass of 1987
Harvard UniversityAB, Biochemistry, Cum Laude, 1978 - 1982

Certifications & Licensure

NJ State Medical License 2024 - 2025
PA State Medical License 1990 - 2024
American Board of Internal Medicine Hematology
Royal College of Physicians and Surgeons of CanadaInternal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2013-2017
America's Top Doctors for Cancer Castle Connolly, 2012-2015, 2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia Start of enrollment: 1993 Jun 01
Completed
Phase 2
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2006 Oct 24
Completed
Phase 2
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Start of enrollment: 2004 Aug 18
Completed
Phase 3
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Start of enrollment: 2007 Dec 01
Completed
Phase 2
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies Start of enrollment: 2007 Jan 01
Terminated
Phase 1, Phase 2
Infusional C-myb ASODN in Advanced Hematologic Malignancies Start of enrollment: 2002 Sep 01
Completed
Phase 1
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

16 citations
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials.
Chezi Ganzel, Ju-Whei Lee, Hugo F. Fernandez, Elisabeth Paietta, Selina M. Luger
Blood Advances. 2021-11-23
92 citations
Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience.
Chezi Ganzel, Zhuoxin Sun, Larry D. Cripe, Hugo F. Fernandez, Dan Douer
American Journal of Hematology. 2018-08-01
275 citations
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.
Kathryn G. Roberts, Zhaohui Gu, Debbie Payne-Turner, Kelly McCastlain, Richard C. Harvey
Journal of Clinical Oncology. 2017-02-01

Journal Articles

Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia
Areej El-Jawahri, Thomas W Leblanc, Selina M Luger, Bhavana Bhatnagar, Alison R Walker, Amir T Fathi, Andrew M Brunner, Gabriela S Hobbs, Jennifer S Temel, JAMA Oncology
Extramedullary Acute Myeloid Leukemia Presenting in Young Adults Demonstrates Sensitivity to High Dose Anthracycline: Subset Analysis from ECOG-ACRIN 1900
Selina M Luger, Ross L Levine, Martin S Tallman, Haematologica
Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium Difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients
Edward A Stadtmauer, James K Mangan, Elizabeth O Hexner, David L Porter, Daria V Babushok, Jacqueline Smith, Craig W Freyer, Mindy Schuster, Noelle V Frey, Selina M Lu..., Clinical Infectious Diseases
Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia
Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature
Join now to see all

Abstracts/Posters

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Selina M. Luger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults
Selina M. Luger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
Selina M. Luger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
Selina M. Luger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
Selina M. Luger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling
Selina M. Luger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integr...
Selina M. Luger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particular...
Selina M. Luger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Meet the Blood Editors
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network TrialDecember 2022
A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 TrialDecember 2022

Press Mentions

FDA Approves Obecabtagene Autoleucel for Acute Lymphoblastic LeukemiaNovember 12th, 2024
myeloMATCH Program Opens Enrollment for Acute Myeloid Leukemia and MDSOctober 22nd, 2024
Improving Care for Patients with Acute Lymphocytic LeukemiaJuly 30th, 2024
Join now to see all